Meeting
2024 ASCO Gastrointestinal Cancers Symposium
Preclinical analysis and clinical validation to identify biomarkers of regorafenib efficacy in patients with metastatic colorectal cancer.
Authors
Mitsukuni Suenaga
Clinical Oncology, Tokyo Medical and Dental University, Tokyo, Japan
Mitsukuni Suenaga , Tetsuo Mashima , Naomi Kawata , Shingo Dan , Hiroyuki Seimiya , Kensei Yamaguchi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Colorectal Cancer,Anal Cancer
Sub Track
Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr 171)
DOI
10.1200/JCO.2024.42.3_suppl.171
Abstract #
171
Poster Bd #
K19
Abstract Disclosures
Similar Posters
Poster
2018 Gastrointestinal Cancers Symposium
Matrix metalloproteinase-related gene polymorphisms to predict efficacy of regorafenib in patients with metastatic colorectal cancer.
First Author: Mitsukuni Suenaga
Poster
2018 Gastrointestinal Cancers Symposium
Identification of biomarkers for TAS-102 efficacy in metastatic colorectal cancer patients based on preclinical analysis and clinical validation.
First Author: Mitsukuni Suenaga
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Regorafenib plus FOLFIRI with irinotecan dose escalated according to UGT1A1 genotyping in patients with metastatic colorectal cancer.
First Author: Chao-Yuan Wang
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Impact of early tumor shrinkage and depth of response in patients with BRAF V600E-mutant metastatic colorectal cancer.
First Author: Shohei Udagawa